Theralase Technologies (TSE:TLT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies, a company focusing on innovative cancer treatments, reported a decrease in revenues and a net loss for the nine-month period ending September 30, 2024. Despite a significant international sales increase, overall revenue dropped by 12%, while operating expenses were reduced by 7%.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.